EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Beyond antibiotics: phage-encoded lysins against Gram-negative pathogens

Sanket Shah, Ritam Das, Bhakti Chavan, Urmi Bajpai, Sarmad Hanif, Syed Ahmed

Frontiers in Microbiology · 08.09.2023 · 14

DOI: 10.3389/fmicb.2023.1170418 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Microbiology, online erschienen am 08.09.2023. Verfasst von Sanket Shah und 5 weiteren Autor:innen. Beteiligte Einrichtung: Techinvention Lifecare Private Limited, Mumbai, India. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibiotics remain the frontline agents for treating deadly bacterial pathogens. However, the indiscriminate use of these valuable agents has led to an alarming rise in AMR. The antibiotic pipeline is insufficient to tackle the AMR threat, especially with respect to the WHO critical category of priority Gram-negative pathogens, which have become a serious problem as nosocomial and community infections and pose a threat globally. The AMR pandemic requires solutions that provide novel antibacterial agents that are not only effective but against which bacteria are less likely to gain resistance. In this regard, natural or engineered phage-encoded lysins (enzybiotics) armed with numerous features represent an attractive alternative to the currently available antibiotics. Several lysins have exhibited promising efficacy and safety against Gram-positive pathogens, with some in late stages of clinical development and some commercially available. However, in the case of Gram-negative bacteria, the outer membrane acts as a formidable barrier; hence, lysins are often used in combination with OMPs or engineered to overcome the outer membrane barrier. In this review, we have briefly explained AMR and the initiatives taken by different organizations globally to tackle the AMR threat at different levels. We bring forth the promising potential and challenges of lysins, focusing on the WHO critical category of priority Gram-negative bacteria and lysins under investigation for these pathogens, along with the challenges associated with developing them as therapeutics within the existing regulatory framework.

Schlagwörter

Stichwörter der Autor:innen

Acinetobacter baumanniiEnterobacteriaceaeGram-negative bacteriaPseudomonas aeruginosaantimicrobial resistancephage-encoded lysins

Autor:innen und Institutionen

  • Techinvention Lifecare Private Limited, Mumbai, India.
  • Department of Biomedical Science, Acharya Narendra Dev College, University of Delhi, New Delhi, India.

Zitieren

APA

Shah, S., Das, R., Chavan, B., Bajpai, U., Hanif, S., & Ahmed, S. (2023). Beyond antibiotics: phage-encoded lysins against Gram-negative pathogens. Frontiers in Microbiology, 14. https://doi.org/10.3389/fmicb.2023.1170418

Vancouver

Shah S, Das R, Chavan B, Bajpai U, Hanif S, Ahmed S. Beyond antibiotics: phage-encoded lysins against Gram-negative pathogens. Frontiers in Microbiology. 2023;14. doi:10.3389/fmicb.2023.1170418

BibTeX
@article{Shah2023,
  author = {Shah, Sanket and Das, Ritam and Chavan, Bhakti and Bajpai, Urmi and Hanif, Sarmad and Ahmed, Syed},
  title = {Beyond antibiotics: phage-encoded lysins against Gram-negative pathogens},
  journal = {Frontiers in Microbiology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fmicb.2023.1170418}
}
Kostenlos starten →